Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Sells $282,600.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Nassim Usman sold 20,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total transaction of $282,600.00. Following the transaction, the director now owns 1,636 shares in the company, valued at approximately $23,116.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Gyre Therapeutics Stock Up 7.4 %

GYRE opened at $15.14 on Friday. Gyre Therapeutics, Inc. has a 1-year low of $3.13 and a 1-year high of $30.40. The company has a 50-day moving average of $17.64.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.